Select country set
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

sTRAIL/Apo2L Human E. coli

  • Regulatory status:RUO
  • Type:Recombinant protein
  • Source:E. coli
  • Other names:TNF-related apoptosis-inducing Ligand, TNFSF10, Apo2 Ligand, TL2
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

RBG10330010 10 µg
RBG10330050 50 µg
RBG10330100 100 μg
PubMed Product Details
Technical Data


Recombinant protein


TRAIL/Apo2L is a cytotoxic protein, which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL-induced apoptosis is achieved through binding to two death-signaling receptors, DR4 and DR5. These receptors belong to the TNFR superfamily of transmembrane proteins, and contain a cytoplasmic “death domain”, which activates the cell's apoptotic machinery. The full length human TRAIL/Apo2L is a 281 amino acid protein, consisting of a 17 amino acid cytoplasmic domain, a 21 amino acid transmembrane domain, and a 243 amino acid extracellular domain. Recombinant Human soluble TRAIL/Apo2L is a 168 amino acid polypeptide (19.6 kDa), consisting of the TNF-homologous portion of the extracellular domain of the full length TRAIL/Apo2L protein.

Amino Acid Sequence



E. coli



Biological Activity

Assay#1:Determined by its ability to induce apoptotic cell death in TRAIL-sensitive U343MG cells. The expected ED50 for this effect is 1.0–3.0 ng/ml. Assay#2:Measured by its ability to induce apoptosis in LN-18 cells (human glioblastoma cells). The expected ED50 for this effect is 0.8 – 2.0 ng/ml.


Endotoxin level is <0.1 ng/μg of protein (<1EU/μg).


Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.5–1.0 mg/ml. Do not vortex. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at –20°C to –80°C.




Research topic


Related Products Docs